相关实验视频

Updated: Sep 19, 2025

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

定量[⁸⁹Zr]Zr-Trastuzumab PET和扩散权重MRI用于表征转移性HER2-阳性乳腺癌与PET/MRI

Ameer Mansur¹, Jonathan E McConathy^2,3, Erica Stringer-Reasor^2,4

¹Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

|June 5, 2025

概括

这项研究结合了[89Zr]Zr-trastuzumab PET和DW-MRI,以非侵入性地评估转移性乳腺癌中的HER2表达. 综合方法改善了病变的表征,并揭示了内异质性,有助于评估治疗反应.

科学领域:

在瘤学瘤学.
医疗成像医学成像
放射化学放射化学是指辐射化学.

背景情况:

目前用于乳腺癌的HER2评估方法是侵入性的,错过了瘤异质性.
核成像和核磁共振 (MRI) 提供对HER2表达和瘤特征的非侵入性全身评估.

研究的目的:

量化来自[89Zr]Zr-trastuzumab PET和DW-MRI的成像指标,以表征HER2阳性转移性乳腺癌.
探索将PET/MRI结合用于内息地绘制和评估对HER2向治疗的反应.

主要方法:

15名HER2阳性乳腺癌患者同时接受了[89Zr]Zr-trastuzumab PET/MRI.
全身明显扩散系数 (ADC) 地图是从扩散权重MRI (DW-MRI) 中生成的.
定量指标 (SUV,ADC) 和多参数映射用于内特征.

主要成果:

恶性组织的[89Zr]Zr-trastuzumab吸收明显高于正常组织.
ADC映射增强了病变特征,特别是在大脑,软组织和骨.
当与ADC映射相结合时,单独PET的诊断准确性从0.59提高到0.75.

结论:

将[89Zr]Zr-trastuzumab PET与DW-MRI结合起来,为在转移性乳腺癌中特征HER2表达和细胞密度提供了一个多参数方法.
这种组合有助于评估治疗反应和瘤异质性.
临床整合需要进一步的大规模验证.

关键词:

这是一种DW-MRI.在HER2 PET/MRI中使用.HER2阳性的转移性乳腺癌.[89Zr]Zr-trastuzumab 的使用情况多个参数的多个参数.

更多相关视频

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET